Therapeutic Goods Administration Investigates Guillain-Barre Syndrome-AstraZeneca Link

Therapeutic Goods Administration (TGA) opened an investigation regarding a rare illness that can leave patients paralyzed after they had the AstraZeneca vaccine.

There were eight cases of rare illnesses were diagnosed in Australia.

TGA said that there was a possible link between Guillain-Barre Syndrome (GBS) and the AstraZeneca COVID-19 vaccine remains under investigation in Australia and internationally.

“As of 19 May 2021, we have received eight reports of GBS in patients vaccinated with the AstraZeneca COVID-19 vaccine,” it added.

TGA continues to monitor and investigate Australian adverse event reports for GBS.

GBS is a rare immune system disorder that causes nerve inflammation and can result in severe pain, numbness, muscle weakness, and difficulty walking.

“Three are newly reported confirmed cases – one in a 57-year-old woman from Victoria, one in a 53-year-old man from South Australia, and the final case in an 18-year-old woman in Queensland,” the report said. 

The report also said that there was an earlier case in a 79-year-old Victorian man that has now been confirmed as meeting the diagnostic criteria. 

“Two other new cases, in an 87-year-old woman from South Australia and a 71-year-old woman from Victoria, were deemed probably related to the vaccine, but more clinical information is required for any confirmations to be made,” the report added.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.